Exalenz Of Israel, Pfizer Of U.S. In Deal With FDA-Approved Test Kit
This article was originally published in PharmAsia News
Israel's Exalenz Bioscience has signed a replacement deal with U.S.-based Pfizer to use the BreathID noninvasive diagnostic kit to test Pfizer drugs for treating gastrointestinal disorders
You may also be interested in...
Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.